Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
13.48
+0.88 (+6.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
Next >
Expert Ratings for Travere Therapeutics
September 22, 2023
Via
Benzinga
Micron Technology To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Friday
September 22, 2023
Loop Capital increased the price target for Splunk Inc. (NASDAQ: SPLK) from $135 to $157. Loop Capital analyst Yun Kim downgraded the stock from Buy to Hold. Splunk shares fell 0.1% to $144.25 in...
Via
Benzinga
Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
September 21, 2023
William Blair downgraded Travere Therapeutics Inc (NASDAQ: TVTX)
Via
Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
September 21, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
September 21, 2023
Via
Benzinga
Analyst Ratings for Travere Therapeutics
September 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
August 18, 2023
Via
Benzinga
Earnings Scheduled For August 3, 2023
August 03, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.
Via
Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 21, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday.
Via
Benzinga
Why Shares of Travere Therapeutics Are Slumping Thursday
September 21, 2023
A mixed trial could hurt a kidney drug's chances of full approval.
Via
The Motley Fool
Why Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-Low
September 21, 2023
It's now up to the FDA whether the company's key drug remains on the market.
Via
Investor's Business Daily
Exposures
Product Safety
Expert Ratings for Travere Therapeutics
July 18, 2023
Via
Benzinga
Analyst Ratings for Travere Therapeutics
June 07, 2023
Via
Benzinga
11 Analysts Have This to Say About Travere Therapeutics
May 22, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
During the session on Thursday, 461 stocks hit new 52-week lows.
Via
Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
September 21, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
September 21, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
September 21, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 21, 2023
Via
Benzinga
Broadcom, KB Home And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 21, 2023
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Evercore ISI Group Maintains Outperform Rating for Travere Therapeutics: Here's What You Need To Know
September 19, 2023
Via
Benzinga
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
September 08, 2023
Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.
Via
Benzinga
3 Small-Cap Stocks That Could Be Big-Time Winners
July 22, 2023
These stocks come with significant risks. But they could generate huge returns over time.
Via
The Motley Fool
Biotech Stock Travere Therapeutics Is Trading At A Deep Discount: JPMorgan
July 21, 2023
Travere Therapeutics shares have lost nearly 30% since early May.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation
July 17, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) has agreed to sell its bile acid product portfolio that, which includes Cholbam (cholic acid) and Chenodal (chenodiol), two medications, to Mirum Pharmaceuticals...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
July 17, 2023
Via
Benzinga
Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire
July 05, 2023
Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.
Via
Investor's Business Daily
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
These promising biotech stocks are risky but offer tremendous upside generating stellar long-term returns in the upcoming 12 months.
Via
InvestorPlace
3 Biotech Stocks With Blockbuster Potential
May 24, 2023
Although risky, these biotech stocks with blockbuster potential may skyrocket should regulatory winds favor their therapeutics.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit